Shanghai Henlius Biotech, Inc. (HKG:2696)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
69.00
+4.25 (6.56%)
At close: Mar 6, 2026
146.43%
Market Cap 37.50B
Revenue (ttm) 6.35B
Net Income (ttm) 903.25M
Shares Out 543.49M
EPS (ttm) 1.66
PE Ratio 41.52
Forward PE 40.02
Dividend n/a
Ex-Dividend Date n/a
Volume 1,273,200
Average Volume 1,381,951
Open 64.75
Previous Close 64.75
Day's Range 64.70 - 69.35
52-Week Range 23.00 - 92.00
Beta 0.59
RSI 57.27
Earnings Date Mar 20, 2026

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 3,537
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2696
Full Company Profile

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.